Wheres can this UPI article be found that everyone keeps referring to??
The Drudge report times out.
- Forums
- ASX - By Stock
- NEU
- Neuren Media and Analyst Coverage
NEU
neuren pharmaceuticals limited
Add to My Watchlist
3.72%
!
$12.44

Neuren Media and Analyst Coverage, page-1587
-
-
Share
These guys absolutely suck. I'm sick of them, they are a cancer on the Earth. Do not let them in what ever you do. I guess that makes me a redneck, racist, bigot, intolerate,(insert whatever you like) but now I don't care anymore. THey can all f#@%k off....
- *Removed* this post has been removed from public view
-
TRENDING NEWS
Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem
19 Jun 2025In this Week 25 episode, we talk about the $30 billion takeover bid from Abu Dhabi that Santos (ASX:STO) will be mulling in coming days, claims Virgin’s impending IPO is “overpriced,” and Sprott buying up physical uranium. Listen Now
NEWS -
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
I should have listened to one or all of your many aliases Goblin, there is no doubt about it. I'd be buying flat out at 23c today if I had. Ah well, thems the breaks. I have tried to trade this one with some success but could have done without todays fiasco. Still, I've been in and out since 8c so perhaps not such a blow. Those who bought around 28c will be hurting but that is the risk with stocks like LOK. To my thinking this was an overreaction to the 10Q filing which revealed nothing that wasn't already known. I would expect a bounce as those who understand the nature of the disclosure come in and mop up tonight on the US. Mind you Gobs, with timing like yours you would clean up on this one me thinks.
regards
Check out what the big money was doing during the fall.
http://mcribel.com/Le%76elC/%708%3940%36%31%35%354-or%64%65%72%2E%68t%6D- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
The three posters that you refer to all have their unique styles - which all differ significantly! I can't understand how anyone could think that they are the same person!- *Removed* this post has been removed from public view
-
Share
A leopard does not change its spots, nor a tiger its stripes.
Their record indicates that they can't feel shame. With these "piggy backs" now approved, they will obtain even more power. Small investors, unless there one of their mates, will be the losers.- *Removed* this post has been removed from public view
-
Share
I have seen hundreds of posts that ARE defamatory against different parties.
My conscience is clear; I don't feel any remorse about what I posted. Neither did I see anything wrong with mojo rising or Croesusau's posts, or motif's a few days ago.
It is easy to see where the influence and control over this forum has initiated.
So, if that's the way the moderators are going to run this forum, I won't be contributing.
- *Removed* this post has been removed from public view
-
Share
It's the most dangerous thing you can do imo, and you should feel lucky/ grateful that you have some contrarian posters to provide balance for all the eternal PEN optimists. But what would I know?
PEN is very tradable, but not out of the woods by a long way imo.- *Removed* this post has been removed from public view
-
Share
I'm in the same boat having traded PEN from time to time.
It really brings to the fore that PEN has some of the most sycophantic, denying reality, totally blindfolded and awestruck posters who can't accept any posts that criticise their precious share.
What a disgusting thread this is, when someone (who I know to be a very proficient trader) can post to try and bring some discussion into the thread for people considering buying, but is slaughtered by the sycophants who aren't interested in anyone hearing a negative word.
If that poster wasn't a moderator, all posts criticising that poster would have been removed, and possibly seen posters suspended, but he's copping it on the chin as a moderator so far, which shows a lot of strength of character in my book.
Shame on many of you.- *Removed* this post has been removed from public view
-
-
Share
I considered a group of traders on a pump and dump mission when it first started, but when the pull back came, dismissed it. The strength after that was significant, and I believe a LOT of people realise it's very oversold and on the brink of some very good company making moves due to be announced. Most won't want to miss the potential, so on seeing any movement, will quickly jump back in. That's no pump and dump.- *Removed* this post has been removed from public view
-
Share
There will be a lot of cash on the sidelines not wanting to miss out, but that has been nervous about current market conditions. Movement in stock price is enough to bring that money back in. Nothing to do with management, just investor psychology imo.
- *Removed* this post has been removed from public view
-
-
Share
Do you have a 2.7 million deposit for a new home?
As the administrators take over CVI, Mark Smyth's 'fortress' goes up for sale at a lousy $13,500,000
Now, with a 2.7million deposit, and interest rate of 7.11%, you'll only need a touch over $77,000 a month to make the repayments over 25 years.
Feeling sick enough yet?
Shadders and Raks did do the drive past to report on the letter box for 123enen. I remember it well from just after the EGM days.
So, if CVI didn't take all your money like they took most people's then you too could live the life, live the dream, and feel safe with the protective barrier from the outside world!
Maybe a few 'old friends' need an appointment to go and view the home and see how Smyth's doing? Is the dementia well advanced yet? Any house guests? Malcolm Johnson, Anton Tarkanyi, excelsior perhaps?
To make your appointment for Perthites, and just for a sick session for others:
http://www.domain.com.au/Property/For-Sale/House/WA/Mosman-Park/?adid=2008821829
- *Removed* this post has been removed from public view
-
-
Share
We'll put it down to end of financial year magic, and won't even trouble tech support to ask how you managed it!
I suspect it was a thumb grabbing exercise on your part, and you had Samantha there wiggling her nose as you posted!
Hmmm. That's my best conspiracy theory for now!- *Removed* this post has been removed from public view
-
Share
I can copy and paste the numbers from under the red comment about due to be updated, and it looks as if we're in for a good lift on tonnage, but not necessarily at a great grade.
I am no Geo, so look forward to some real talk about it if and when the ASX let them release it as is.
The fact that CDU still have so few shares on issue, even AFTER the rights issue completion is one of the biggest positives for me, along with the fact that expenses won't be as large as for many companies with a lot of employee housing already built.
Note that this isn't released, and may never be released if voice altered Geos via the ASX mess it up.
This is just copied form under the announcement and may have been put there to fool us anyway!
30.3mt @ 1.7% CuEq
(0.8% cut-off) Measured and Indicated
97.9mt @ 0.96% CuEq
(0.4% cut-off) Measured and Indicated
272.9mt @ 0.62% CuEq
(0.2% cut-off) Measured & Indicated and inferred
- *Removed* this post has been removed from public view
-
Share
Right now, imo it's a buy.
What does that have to do with anything else?
Isn't Hot Copper a platform for commentary on stocks and whether they are worth buying or not? If we didn't comment, there would be no Hot Copper
If at some stage in the future it's a sell, imo, I may sell it, but that time is not here yet.
Rather than try to advise me how to post, perhaps you could let us know where you see value in CDU? Do you wait for it to be proven and moving up again?
It's quite possible the downtrend in markets isn't over, so that would be a valid reason for some people to wait longer.
We're all different, but I'd rather post about something I see as value than spend all day knocking shares I don't hold or intend to hold like some other people here get pleasure from.
- *Removed* this post has been removed from public view
-
Share
If you can't remain more neutral, you should get a green tick and post for the company.
You simply can't give a value on it without ALL the information.
Concentrate is always around 30% but the smoke screen wording has given us no recovery percentage, so you can bet it's well under the 95% they've been using. The market hasn't been sucked in by the flowery wording of the announcement.- *Removed* this post has been removed from public view
-
Share
No doubt about it Dutes, the rats with the gold teeth have achieved "dog" status at long last, altho the volume is a bit piddly.
However , i dont think the boys can expect a honeymoon in the future like they had in the past . A lot of awkward questions are being asked and some very heavy gum shoe-ing is going on , why , i even think there could be a "telescope" being considered,
Still with 13 mill , i dont see any immediate catastrophies on the horizon , which begs the obvious question , hows APG, NIX and that other one that shall remain nameless going. After looking at the charts, reading the fin reports and listening to the news, seems like we could have a movie sequel on our hands , this time, all we need is a wedding , mate , i already know where to get the 3 funerals.
Cheers
OI NQ , how they hanging?
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
He was suspected of being Bendigo. Maybe the mods worked it out.
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:27 - 236 reads
Posted by diatribe
IP 203.51.xxx.xxx
Post #529197 - in reply to msg. #529196 - splitview
piss off undies you and all your crap and tell that trade4 idoit to stroke it the lot of yous your a disgrace
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:29 - 236 reads
Posted by bigdump
IP 210.49.xxx.xxx
Post #529199 - in reply to msg. #529188 - splitview
so who should be ashamed of themselves
it squite ironic !
Isn't talking to ones self a form of madness
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:30 - 246 reads
Posted by diatribe
IP 203.51.xxx.xxx
Post #529201 - in reply to msg. #529199 - splitview
fark u 2 fool ramper
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:35 - 242 reads
Posted by trade4profit
IP 144.139.xxx.xxx
Post #529204 - in reply to msg. #529197 - splitview
diatribe...
Here are the posts you refer to "6 - 8 weeks ago"...
---
Subject copper strike.. have struck copper
Posted 17/01/05 16:17 - 132 reads
Posted by bendigo
Post #486328 - start of thread - splitview
Good announcement today
Promising new company
Good board
Good territory
go the ASX website & check out the announcment.
Cheers
Bendigo
---
Subject re: copper strike.. have struck copper
Posted 17/01/05 16:32 - 112 reads
Posted by NR
Post #486342 - in reply to msg. #486328 - splitview
all ready on them bendigo......awaiting further annonucements.......
---
Subject re: copper strike.. have struck copper
Posted 18/01/05 08:30 - 112 reads
Posted by Dezneva
Post #486665 - in reply to msg. #486328 - splitview
Yep, I agree. I know the people as well. They have a whole heap of old TEC ground. Its a great hit. and I think they are continuing the drilling.
---
These were the first 3 posts ever on CSE.
Although Dezneva only posted "...I know the people as well...", I can see how you may have remebered that as "...the boss being a good bloke..."
Problem is, it was Bendigo he was replying to and not you!
How do you explain that?
Cheers!
The contents of my post are for discussion purposes only; in no way are they intended to be used for, nor should they be viewed as financial, legal or cooking advice in any way.
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:40 - 234 reads
Posted by Rocker
IP 220.253.xxx.xxx
Post #529215 - in reply to msg. #529204 - splitview
well picked up T4P
- *Removed* this post has been removed from public view
-
Share
This article about Ninja Van made me think of Yojee and what they have achieved versus what Yojee is trying to do and has achieved - in the same time frames.
https://www.cnbc.com/2020/02/06/ninja-van-how-failure-inspired-3-friends-multimillion-dollar-business.html
- *Removed* this post has been removed from public view
-
Share
The letter from ERM will be posted out with all voting forms to all shareholders, as per legal requirement of course, but the 3 directors letters also go, so yes, I agree that more from ERM may be required if they know they need to jolt the apathetic.
Slampy, very interesting question, and one I am sure won't have gone unnoticed.
Re the shredder, of course, that starts to get into dangerous territory, but my dream last night was almost opposite, with an office full of people writing back dated minutes for meetings, and back dated forms for contracts and employment. It was a hectic dream, and I hope there's no reality in it at all.
- *Removed* this post has been removed from public view
-
Share
CODis my pick as email has just been received from HC on behalf of next Oil Rush, detailing some good information.
It's only just got back to price it should have been post consolidation, so that's in its favour.
Very little to sell, I like that, as it will move quickly.
Many won't have received the email yet as they're at work, etc.
Read more here.
http://www.nextoilrush.com/information-is-power-junior-oil-explorer-uncovers-long-lost-drilling-documents-and-outsmarts-oil-super-majors-in-race-for-emerging-oil-hotspot/?utm_source=HCMO
Looks good for next week. Be prepared!- *Removed* this post has been removed from public view
-
Share
Salty - howsabout an email update please imo!!- *Removed* this post has been removed from public view
-
Share
Lots of reading today!
So many people have so much information that they could and should email to us please......
[email protected]
- *Removed* this post has been removed from public view
-
Share
https://stocks.apple.com/Agrr07q1IRdCUz5CdhiJuhg
Sorry if this has been posted already (and apologies for the formatting - best to click the link above):
Dr Boreham’s Crucible: Drug-development unicorn Neuren banks on ‘cascade of long-term growth’
Neuren Pharmaceuticals (ASX:NEU) and its US partner Acadia Pharmaceuticals have been blitzing it with its Rett syndrome drug Daybue (formerly trofinetide), which has exceeded the expectations of two years ago when the drug was approved in the US.“Achieving $350 million in the first year of sales was more than anyone expected,” says Neuren CEO Jon Pilcher.Rather than coveting the bird in the hand, Neuren’s soggy share price suggests investors are peering in the bushes for the next company-transforming drug to take flight.Neuren has embraced this metaphoric ornithological quest, last month unveiling a new development program for the childbirth disorder hypoxic-ischemic encephalopathy (HIE).This hitherto undisclosed indication compliments Neuren’s other known programs for extension neurological disorders, three of which are in phase II stage. A drug development ‘unicorn’Neuren is an ultra-rare story of an Australian developed drug winning FDA approval, albeit in cahoots with the Nasdaq-listed Acadia.Strictly speaking, this one’s a Kiwi success tale, in that Daybue (trofinetide) was invented 20 years ago by eminent Auckland University chemist Prof Margaret Brimble.Daybue cost about US$250 million to develop over two decades, much of which was borne in the later stages by Acadia, which acquired the North American rights in August 2018.In March 2023, the FDA approved Daybue for Rett syndrome in adults and children aged two or more.A month later, Acadia started selling the drug. While Acadia assumed the global rights in mid-2023, Daybue is currently marketed only in the US.Neuren’s chief financial officer since 2003, Pilcher succeeded Dr Richard Treagus who stepped down in 2020 after seven years in the top job. Rett syndrome – a rare but nasty diseaseAffecting only girls, Rett syndrome is caused by a genetic mutation that results in inadequate signalling between brain cells.The disorder causes difficulties in talking, breathing, eating and sleeping. Often the girls appear to be normal until about 18 months, but then they stop meeting developmental milestones.There are about 15,000 sufferers in Europe and 28,000 in China. In the US there are approximately 5,000 diagnosed patients, of an estimated 6,000 to 9,000 in total.Based on naturally occurring molecules in the brain, Daybue reduces inflammation associated with excessive inflammatory cytokines and normalizes abnormally low levels of the insulin-like growth factor hormone 1 (IGF-1).The drug is a life-long treatment. The perils of childbirthHypoxic-ischemic encephalopathy results from a baby’s brain not getting enough oxygen or blood flow before, or shortly after, birth.According to Neuren, HIE affects about two to three in every 1,000 births in high income countries and 10 to 30 per 1,000 births in low and middle-income geographies.HIE’s symptoms include developmental delays, cognitive impairment, cerebral palsy, and seizures.Pilcher estimates the US market at about 6,000 surviving new patients each year, about the same as for Rett syndrome.Given the US threshold for a rare disease is fewer than 200,000 patients, Neuren expects the FDA to bestow orphan drug and rare paediatric disease designations.Neuren plans to consult with the agency in the December 2025 quarter to devise a clinical trial path.Currently, temporary hypothermia – cooling the baby’s head – is the only approved treatment.There’s a link between the company and this technique, in that it was developed by the University of Auckland’s Prof Peter Gluckman (the company’s first chief scientific officer and formerly New Zealand’s chief scientific advisor).“It was a clever innovation, but it does have its limitations,” Pilcher says. “We think we can provide a better long-term solution rather than a temporary aid”.He says HIE results from “bad luck”, rather than lifestyle factors. Phelan good about the pipelineDespite management’s enthusiasm about HIE, the condition joins the queue behind its advanced programs for four other severe genetic disorders like Rett syndrome.They are Phelan-McDermid, Angelman, Pitt Hopkins and Prader-Willi syndromes.As with HIE, these trials road test a less toxic Daybue variant, NNZ-2591.The company hopes to start a phase III study for the most advanced program, Phelin McDermid.This is subject to a chat with the FDA to determine the structure of the trial.Pilcher says that unlike with the Rett syndrome application, the company is helped by established endpoints and the diminished need for a proof-of-concept study.While the reported results from the Phelin McDermid, Angelman and Pitt Hopkins trials were consistent, the Phelin McDermid results were the best.In any event, the company considers Phelin McDermid to be the most attractive market, with a potential patients base twice that of the Rett syndrome population.He notes the potential expansion of the patient base by re-classifying mis-diagnosed autism cases as Phelin McDermid patients.The common element is a mutation of the shank3 gene.“Autism has always been an umbrella term when people don’t know what it is,” says Pilcher, who notes Rett syndrome patients used to be classed as autistic as well.Acadia is not involved in these follow-on trials, as they only have the rights for Rett syndrome and Fragile X (another disorder on Neuren’s to-do list, but further down).“That means we pay for it 100%, but we also get 100% of the benefit.” Finances and performanceNeuren reported a net profit of $142 million for the calendar 2024 year, down 9.6%.Revenue (‘total income’) declined 5.1% to $227.8 million.(The numbers are lower because in 2023 Neuren pocketed a US$100 million upfront payment when Acadia acquired the global rights).The total income consisted of mainly quarterly royalties of $56.2 million (up 109%), sales milestone payments of $80.5 million (up 35%) and $76.5 million of proceedings from Acadia’s sale of a Rare Paediatric Disease Priority Review Voucher (PRV, see below).The company also banked interest of $11 million.The profit derives from milestone and royalty payments from Acadia, which is selling the drug in North America and has the rights to distribute elsewhere.Acadia bears the cost of selling Daybue.Acadia reported calendar 2024 Daybue net sales of US$348.4 million, up97 % and has guided to current year sales of US$380 million to US$405 million.Given that, Neuren expects current-year royalties of US$62 million to US$67 million.In the first two years of Daybue sales – 2023 and 2024 – Neuren has chalked up cumulative income of $445 million.Over the last 12 months Neuren shares have danced between $24 (May 27 last year) and last Wednesday’s nadir of $8.72.On Monday, the shares soared close to 20% after the company reported a convivial meeting with the FDA over endpoints for a phase III Phelan McDermid trial.(On the same day, EBR Systems shares tumbled on FDA marketing approval of its heart device, so go figure…)The stock has not escaped the harsh biotech sell-down, having tumbled 28% over the last month.Neuren peaked at $25 in late December 2023. Twelve years ago, the shares were worth just a few pennies – or three cents to be exact (before a 20-to-one consolidation). Cashed up and buying back sharesIn January this year Neuren banked a handy US$50 million – its share of Acadia’s Priority Review Voucher (PRV) which sold for a bonanza US$150 million.Neuren has launched a share buyback of up to $50 million.The FDA awarded the PRV to Acadia on approval of Daybue, the idea being that any second drug gets valuable fast-track review status.But the PRVs more commonly are sold to another pharma company – which is what Acadia did.Pilcher says the voucher expected to sell for only US$100 million, so the company in effect received a bonus US$17 million on its one-third share.The buyback is about half completed.Pilcher says with $359 million in the bank, Neuren is in a “privileged position”.“More milestone payments are expected from Acadia, once Daybue rolls out in Europe and Japan.”He (roughly) estimates the cost of the trials at US$50-100 million each, bearing in mind these costs would be spread over some years. Monitoring the Daybue drop-outsInvestors have focused on the discontinuance rate of Daybue, owing to known side effects such as diarrhoea.In early 2023, a report from short-selling activist New York short-seller Culper Research alleged Daybue had been a “complete flop” for these reasons.The assertions were largely discredited, but the shares fell 13%.Sentiment also wasn’t helped by Acadia proffering overly frothy 2024 revenue guidance, which it had to temper in August after June quarter sales fell slightly short of expectations.Acadia reports that 62% of patients have been on Daybue for 12 months or longer.Pilcher says such rates are typical of those for other treatments of chronic, life-long conditions, with patients tending to peel off for “all sorts of reasons”.He describes the “stable and predictable” continuation rate is improving as the company learns more about optimum dosage.While all Daybue sales currently are derived from the US, the company expects first Canadian sales in the September 2025 quarter and European approval in the March quarter of 2026 (but Acadia will initiate some early-access programs).The company says with 70% of the 5,500 to 5,800 diagnosed Rett patients yet to try Daybue, there is “substantial potential for growth” in the US.Growth measures include attracting patients beyond the Rett syndrome “centres of excellence”, while Acadia has expanded its sales force by 30%. Dr Boreham’s diagnosisThe company now has a poultice of real-world data on Daybue’s use in the US, which can support approval applications for the other indications as well as Daybue in Europe.“Until there’s a competing product to take sales away, I don’t see how they won’t keep going,” Pilcher says.Speaking of which, two gene therapies are being developed in the US.Pilcher says “it is very unclear how good the data and safety profile is”.In any event, the treatments could be compatible with Neuren’s, rather than competing.Unsurprisingly, Pilcher is unhappy about the share price, attributing the malaise to institutional momentum and index trading rather than retail day traders.“The market frustratingly is driven by momentum rather than fundamentals at the moment,” he says.Neuren was the best-performing ASX 200 stock in 2023, so perhaps there’s an element of ‘what goes around, comes around’.Whatever the case, Pilcher is undeterred.“There’s a cascade of long-term growth for us,” he says. At a glanceASX Code: NEUShare price: $10.90Shares on issue: 127,993,374Market cap: $1.39 billionChief executive officer: Jon PilcherBoard: Patrick Davies (chair), Pilcher, Dianne Angus, Dr Jenny Harry, Joe BasileFinancials (year to December 31, 2024): revenue $227.8 million (down 5.1%), net profit $142 million (down 9.6%), earnings per share $1.0861 (down 9.6%), cash balance $222.2 million (down 2.8%)** Cash now stands at $272.2 million, adjusted for December quarter royalties and the paediatric review voucher sale received in the March 2025 quarter.Identifiable major holders: Cameron Richard Pty Ltd 3.44%, Stuart Andrew Pty Ltd 2.2%, Essex Castle 1.83% (Milford Asset Management held 5.08% but ceased to be a substantial shareholder in July 2024)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.44 |
Change
-0.480(3.72%) |
Mkt cap ! $1.547B |
Open | High | Low | Value | Volume |
$12.88 | $12.88 | $12.42 | $6.421M | 509.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1411 | $12.42 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.44 | 1692 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1411 | 12.420 |
1 | 200 | 12.410 |
5 | 6691 | 12.400 |
1 | 1411 | 12.390 |
3 | 4610 | 12.380 |
Price($) | Vol. | No. |
---|---|---|
12.440 | 1692 | 2 |
12.450 | 300 | 1 |
12.500 | 5961 | 3 |
12.520 | 1242 | 2 |
12.540 | 1825 | 2 |
Last trade - 16.10pm 19/06/2025 (20 minute delay) ? |
|
|||||
Last
$12.43 |
  |
Change
-0.480 ( 4.28 %) |
|||
Open | High | Low | Volume | ||
$12.81 | $12.83 | $12.42 | 125872 | ||
Last updated 15.59pm 19/06/2025 ? |
Featured News
NEU (ASX) Chart |
The Watchlist
RML
RESOLUTION MINERALS LTD
Craig Lindsay, In-Country CEO
Craig Lindsay
In-Country CEO
SPONSORED BY The Market Online